Cancer drugs known as BET inhibitors once looked like a breakthrough, but in real patients they’ve often fallen short. New research reveals a key reason why: two closely related proteins, BRD2 and BRD4, don’t actually do the same job. Instead, BRD2 acts like a “stage manager,” preparing genes for activation, while BRD4 triggers the final step that turns them on. By blocking both at once, current drugs may be disrupting the process in unpredictable ways.
source https://www.sciencedaily.com/releases/2026/04/260409101055.htm
Scientists identify kinesin-2 motor assemblies that selectively transport
proteins to specific regions within neurons
-
Intracellular transport is a vital process that allows cells to move
proteins and other molecules to specific locations. This process is
especially importa...
53 minutes ago
No comments:
Post a Comment